The Department of Health and Social Care has provided a significant update in response to a campaign urging revisions in prostate cancer testing. This initiative, driven by a parliamentary petition, sought to expand access to PSA testing for individuals at heightened risk, particularly as prostate cancer ranks as the most common cancer among men in the UK.
PSA tests are utilized by the NHS to assess prostate-specific antigen levels in the blood for detecting prostate issues. Despite their utility, these screenings are not routinely offered within the national healthcare system or included in a widespread screening program.
In response to the petition’s call for a review of NHS guidelines and the establishment of an early detection program, the Government department clarified that it currently has no intentions to mandate proactive PSA blood tests for men at elevated prostate cancer risk due to existing limitations in the testing method. The concerns primarily revolve around the potential for false-positive results, leading to unnecessary procedures and anxiety in individuals without symptoms.
While acknowledging the value of PSA tests in certain diagnostic scenarios, the department underscored the risks associated with false-positive outcomes and the potential harm from unnecessary treatments like biopsies, prostatectomy, and radiotherapy. Additionally, the Government highlighted that elevated PSA levels are not always indicative of prostate cancer, potentially resulting in false-negative results that could provide misleading reassurance.
The UK National Screening Committee, in alignment with the department’s stance, deems the risks of population-level prostate cancer screening to outweigh the benefits. To further evaluate screening approaches, the UK NSC has conducted a comprehensive evidence review, including considerations for targeted screening of high-risk groups such as Black men and those with a family history of cancer.
In a proactive move, the Government has allocated £16 million in collaboration with Prostate Cancer UK for the TRANSFORM trial, a £42 million nationwide study aimed at identifying the most effective methods for prostate cancer detection. Notably, the trial ensures representation from Black men, acknowledging their heightened susceptibility to prostate cancer.
Expressing a commitment to reducing prostate cancer fatalities, the Government affirmed its intent to unveil a National Cancer Plan later this year centered on enhancing patient outcomes and minimizing cancer-related deaths. The petition advocating for enhanced prostate cancer detection and diagnosis has garnered over 12,000 signatures, with the potential for parliamentary debate if it surpasses 100,000 signatures.
For further details on the petition, you can access it here.